NCT Number: NCT00005555
Dose Response to Exercise and Cardiovascular Health
To determine the minimal dose of physical activity necessary to improve cardiovascular (CV) health by evaluating and aerobically training 500 healthy men and women, 30-65 years of age.
Looking for future studies?
Notify MeKey information
Conditions
Age range
30 year–65 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Not applicable
About this study
BACKGROUND:
Results from the study will provide important data regarding the dose of exercise required to improve cardiovascular health, as described both by the NIH Consensus Conference on Physical Activity and CV Health and by the recent Report of the Surgeon General. The study was initiated in response to a Program Announcement released in October 1994 on Physical Activity and Cardiopulmonary Health.
DESIGN NARRATIVE:
Subjects were randomized into one of five groups in a 2x2 factorial design plus a usual care control group (n=100 in each of 5 groups). Subjects trained at a moderate (45-55 percent) or high (65-75 percent of maximum heart rate reserve) intensity, and at a frequency of 3-4 or 5-7 days/week (viz., Group 1, 65-75 percent at 5-7 days/week; Group 2, 65-75 percent at 3-4 days/week; Group 3, 45-55 percent at 5-7 days/weekk; Group 4, 45-55 percent at 3-4 days/week; and, Group 5, usual care control). Controls received advice from a physician to increase their physical activity. The subjects in Groups 1-4 participated in an exercise intervention using walking as the mode of training for a total of 24 months. A lifestyle model of physical activity was used, in that subjects could accumulate exercise minutes during the day in 10-minute increments or more continuously (for a total duration of 30 minutes/day), and training was conducted where it was most convenient for the subject (i.e. at home, work or some combination thereof). Tests occurred at baseline (0), 12, and 24 months of the intervention.
The hypothesis was that Groups 1-4 would show a significant reduction in systolic and diastolic blood pressure and an increase in HDL-cholesterol compared to the usual care control group. A second hypothesis was that that there would be significant main effects for both frequency and intensity, with the higher levels of each producing greater improvement on the major outcome variables compared to the lower levels of each dose. The study also planned to determine the minimal dose response to exercise necessary to elicit significant improvement in cardiovascular and behavioral health factors. Finally, the project included examination of the effects of age and level of initial test values on outcome variables to determine if their interactions affected the results of the intervention.
The study also includes assessment of the effect of specific doses of exercise on the reduction in systolic and diastolic blood pressure and increase in HDL-cholesterol (primary outcomes), in addition to changes in levels of physical activity, aerobic fitness (VO2 max), body composition (percent fat and waist-to-hip ratio), triglycerides, and LDL-cholesterol (secondary outcomes). Psychological variables (depression, anxiety, anger, and perceived stress) and health-related quality of life are also evaluated, and the important issue of adherence to exercise is examined with respect to the effect of dose of exercise.
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
No eligibility criteria
Treatment and study plan
Sponsors and collaborators
Lead sponsor
University of Florida
Other
Collaborators
- National Heart, Lung, and Blood Institute (NHLBI)
Registry information
Important dates
- Study start
- 1998
- Study completion
- 2003
- First posted
- May 26, 2000
- Registry last updated
- Jan 8, 2016
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
CES1 Carriers in the PAPI Study
NCT03188705
Arterial Occlusive Diseases, Arteriosclerosis
Lancaster, Pennsylvania, United States
View Trial DetailsSoy Food and Coronary Heart Disease in Women
NCT00241735
Cardiovascular Diseases, Coronary Disease
View Trial DetailsHOLT-ED: Holter-monitoring in End-stage Renal Disease
NCT04876963
Arrhythmias, Cardiac, Cardiovascular Diseases
Copenhagen, Denmark
View Trial DetailsSapphire 3 CTO Study
NCT06358508
Arterial Occlusive Diseases, Arteriosclerosis
Stanford, California, United States
View Trial Details